News UCB

Equities

UCB

BE0003739530

Market Closed - Euronext Bruxelles Other stock markets 11:35:11 2024-06-06 am EDT			After market 01:31:07 pm
129.9 ^EUR	+0.31%		129.9	+0.02%

Apr. 11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
Apr. 11	UCB : Berenberg, Buy, raises its price target	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UCB : Acquisition of own shares	May. 31	PU
UCB : Commitment to Innovation in Drug Development	May. 29	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	May. 23	PU
UCB - Acquisition of own shares	May. 20	AQ
UCB : Transparency notification Wellington	May. 17	PU
UCB : Acquisition of own shares	May. 17	PU
UCB - Acquisition of own shares	May. 13	AQ
UCB : Acquisition of own shares	May. 10	PU
UCB presents final open-label extension F data at International Child Neurology Congress Annual Meeting	May. 09	AQ
UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	May. 08	PU
UCB : presents final open-label extension FINTEPLA®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	May. 07	PU
UCB - Acquisition of own shares	May. 06	AQ
UCB : Acquisition of own shares	Apr. 26	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	Apr. 26	PU
Ex-dividend day for final dividend	Apr. 25	FA
UCB : General Meeting of Shareholders 2024	Apr. 25	PU
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	Apr. 22	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	Apr. 17	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	Apr. 15	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	Apr. 12	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am EST